Thiel, Parker said to fund secretive T-cell biotech startup

Little is known about the stealthy I-O biotech.

A report from CNBC says that PayPal founder Peter Thiel and Facebook investor Sean Parker are investing in a new, secretive oncology biotech company.

The news service, quoting a “person familiar with the company's financing,” says the so-called 3T Biosciences has raised more than $12 million, with the seed investment being led by Thiel, reportedly once up for the FDA chief role and a serial biotech investor, and Parker, who recently injected $250 million into the immuno-oncology research field in an effort to boost cancer survival rates.

RELATED: Facebook, Napster pioneer Sean Parker sets up $250M immuno-oncology center


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

CNBC, quoting the anonymous source, says the stealthy startup is currently led by a “cancer biology Ph.D. student and investor, Asset Management Ventures’ principal Luke Lee, as well as a group of academics from Christopher Garcia's biology lab at Stanford.”

It’s said to be in the T-cell therapy space, and would add to a growing trend in this form of immuno-oncology upstarts.

It’s not unusual for early-stage biotechs to stay under the radar in their first 12-18 months as they build up seed investment and get through preclinical work.

Suggested Articles

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.

The FDA rejected the New Drug Application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.